Beijing Ledman Biochemical Co., Ltd. and its Directors and Senior Management: Statement and Commitment Regarding the Restructuring Transaction
The Company and all directors and senior management guarantee that the "Report on Major Asset Purchase of Beijing Ledman Biochemical Co., Ltd. (Draft Amendment)" and other application documents are true, accurate, and complete, and do not contain any false statements, misleading representations, or material omissions. If the information disclosure in this restructuring contains false statements, misleading representations, or material omissions, causing losses to investors, the Company and individuals will bear legal liability individually and jointly.
All directors and senior management of the Company promise that if the information provided or disclosed in this restructuring contains false statements, misleading representations, or material omissions, and is investigated by judicial authorities or investigated by the China Securities Regulatory Commission, they will suspend the transfer of their shares in the listed company (if any) before the investigation conclusion is made clear. Within two trading days of receiving the investigation notice, they will submit a written application for suspension of transfer and their stock accounts to the board of directors of the listed company, which will then apply to the stock exchange and the registration and settlement company for lock-up. If the lock-up application is not submitted within two trading days, the board of directors of the listed company is authorized to verify the information and directly report the individual's identity and account information to the stock exchange and the registration and settlement company to apply for lock-up. If the board of directors of the listed company does not report the individual's identity and account information to the stock exchange and the registration and settlement company, the stock exchange and the registration and settlement company are authorized to directly lock up the relevant shares. If the investigation concludes that there are illegal or irregular circumstances, the individual promises that the locked-up shares will be voluntarily used for compensation arrangements for relevant investors.
(No further text on this page)
(This page is intentionally left blank, serving as the signature page for the "Statement and Commitment of Beijing Ledman Biochemical Co., Ltd. and its Directors and Senior Management Regarding the Truthfulness, Accuracy, and Completeness of the Transaction Application Documents")
Signatures of All Directors:
[blank] [blank] [blank]
[blank]
Signatures of All Senior Management:
Beijing Ledman Biochemical Co., Ltd.
2026 June 12
Beijing Ledman Biochemical Co., Ltd. Controlling Shareholder
Commitment Regarding the Truthfulness, Accuracy, and Completeness of Information Provided
Beijing Ledman Biochemical Co., Ltd. (hereinafter referred to as the "Company") intends to acquire the control of Beijing Sinosun Pharmaceutical Co., Ltd. (hereinafter referred to as "Sinosun Pharmaceutical" or the "Target Company") by paying cash to Hainan Baimai Investment Co., Ltd. (hereinafter referred to as "Hainan Baimai"), Hainan Sinosun Baijiahui Technology Development Co., Ltd. (hereinafter referred to as "Hainan Baijiahui"), and Nanjing Baijiarui Enterprise Management Consulting Partnership (Limited Partnership) (hereinafter referred to as "Nanjing Baijiarui", collectively with Hainan Baimai and Hainan Baijiahui referred to as the "Transaction Counterparties") (hereinafter referred to as the "Transaction").
The Company, as the controlling shareholder of the listed company, hereby makes the following commitments:
- The Company guarantees that all materials and information provided for this transaction are true, accurate, and complete, and do not contain any false statements, misleading representations, or material omissions. The Company shall bear individual and joint legal liability for the truthfulness, accuracy, and completeness of the provided materials and information.